At a glance
- Originator Friedrich Schiller University
- Developer Friedrich Schiller University; Nonindustrial source
- Class Antineoplastics; Tyrphostins
- Mechanism of Action Platelet-derived growth factor receptor antagonists; Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Cancer; Reperfusion injury
Most Recent Events
- 19 Sep 2001 Discontinued-Preclinical for Acute myeloid leukaemia in USA (Unknown route)
- 19 Sep 2001 Discontinued-Preclinical for Cancer in Germany (Unknown route)
- 19 Sep 2001 Discontinued-Preclinical for Cancer in USA (Unknown route)